Primary Immune Deficiency

Retrospective Chart Review of Subcutaneous IgG Use in Infants

NCT01166074 | PHASE 2 | OBSERVATIONAL

This study is a retrospective chart review of the use of subcutaneous IgG (SCIG) in infants less than two years old.

5 Sites

27 Participants

Recruiting

12 Years to 2 Years

If interested, contact clinicaltrials@cslbehring.com for more information

Find closest sites:

SUBMIT

Children's Hospital of Los Angeles

Los Angeles,California,United States,90027

University of South Florida

Tampa,Florida,United States,33612

Midwest Immunology Clinic

Plymouth,Minnesota,United States,55446

University Hospitals Case Medical Center

Cleveland,Ohio,United States,44106

St. Judes Children's Research Hospital

Memphis,Tennessee,United States,38105

Inclusion Criteria

* Infants who received more than one dose of IgG by the subcutaneous route before the age of two years.
* Consent of parent/guardian if required by institution/IRB.

Exclusion Criteria

* Infants with protein losing conditions such as lymphangiectasis, nephrosis, S/P cardio-thoracic surgery requiring drainage tubes for more than 48 hrs, protein losing enteropathy.
* Concomitant treatment with plasma, other blood products or IGIV while on SCIG.
* Lack of consent by parent/guardian (if required by Institution/IRB).
* Any other condition or treatment which, in the opinion of the local investigator, would interfere with obtaining valid results for that subject.

Additional studies can be found at ClinicalTrials.gov